跳到主要内容

10x Genomics, Inc. (TXG) Stock Forecast 2025 - AI Price Prediction & Analysis


10x Genomics, Inc. (TXG) AI Stock Price Forecast & Investment Analysis

10x Genomics, Inc. Stock Price Chart and Technical Analysis

Loading 10x Genomics, Inc. interactive price chart and technical analysis...

10x Genomics, Inc. (TXG) - Comprehensive Stock Analysis & Investment Research

Deep dive into 10x Genomics, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about 10x Genomics, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For 10x Genomics, Inc.: 10x Genomics, Inc. operates in the Industrial Applications and Services sector, making it an emerging small-cap investment.

10x Genomics, Inc. (Stock Symbol: TXG) is a leading company in the Industrial Applications and Services sector , specifically operating within the Laboratory Analytical Instruments industry.

The organization employs approximately 500 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing 10x Genomics, Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For 10x Genomics, Inc.: With $644M in annual revenue and -247.1% net margin, the company demonstrates developing profitability.

Annual Revenue: $644 million generating a -247.1% net profit margin .

Market Capitalization: $1571 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -11.4% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for 10x Genomics, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Accuracy scores show historical prediction reliability.

For 10x Genomics, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for 10x Genomics, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: 10x Genomics, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For 10x Genomics, Inc.: Market positioning analysis based on available financial and operational metrics.

10x Genomics, Inc. strategically competes in the highly dynamic Laboratory Analytical Instruments marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy 583.1% gross margin, indicating strong pricing power and operational efficiency.

10x Genomics, Inc. (TXG) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for 10x Genomics, Inc. stock analysis.

Loading 10x Genomics, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into 10x Genomics, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if 10x Genomics, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For 10x Genomics, Inc.: With a P/E ratio of -8.57, the market sees the stock as potentially undervalued.

P/E Ratio -8.57x
P/B Ratio 2.03x
Market Cap $1571M
EPS $-0.70
Book Value/Share $6.22
Revenue/Share $5.19
FCF/Share $-1.05
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently 10x Genomics, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For 10x Genomics, Inc.: An ROE of -11.4% indicates room for improvement in shareholder value creation.

ROE -11.4%
ROA -9.1%
ROIC -10.3%
Gross Margin 583.1%
Operating Margin -278.0%
Net Margin -247.1%
EBT Margin -16.9%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess 10x Genomics, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For 10x Genomics, Inc.: A current ratio of 7.38 indicates strong liquidity.

Current Ratio 7.38x
Quick Ratio 6.52x
D/E Ratio 0.12x
Financial Leverage 1.24x
Interest Coverage -108.1x
Working Capital $656M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal 10x Genomics, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For 10x Genomics, Inc.: Free cash flow of $-129M indicates cash challenges that need attention.

Operating Cash Flow $-38M
Free Cash Flow $-129M
Capital Spending $-91M
FCF/Sales -25.8%
CapEx/Sales 18.1%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively 10x Genomics, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For 10x Genomics, Inc.: An asset turnover of 0.51x suggests room for improvement in asset utilization.

Asset Turnover 0.51x
Receivables Turnover 7.5x
Inventory Turnover 1.6x
Fixed Assets Turnover 2.3x
Days Sales Outstanding 49 days
Days Inventory 226 days
Payables Period 76 days
Cash Conversion Cycle 199 days
Understanding Financial Statement Data

What these metrics mean: Key figures from 10x Genomics, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For 10x Genomics, Inc.: With annual revenue of $644M, 10x Genomics, Inc. demonstrates solid business size.

Income Statement ($ Millions)
Total Revenue $644M
R&D Expense $47M
SG&A Expense $54M
Cost of Goods Sold $223M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 70%
Cash & Short-term Investments 54%
Total Liabilities 20%
Short-term Debt 2%
Accounts Receivable 8%
Inventory 6%
Dividend & Shareholder Information
Shares Outstanding 124M
Growth Metrics (YoY)
EPS Growth -10.5%

Latest 10x Genomics, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting 10x Genomics, Inc. (TXG) stock price and investment outlook.

, source: Seeking Alpha

PLEASANTON, Calif., Aug. 7, 2025 /PRNewswire/ -- 10x Genomics, Inc. (TXG) (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has signed a definitive agreement to ...

10x Genomics, Inc. Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of 10x Genomics, Inc. against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
A Unlock Forecast - 30 Days FREE Trial $35123M 28.8x 5.5x
AKYA Unlock Forecast - 30 Days FREE Trial $64M -2.1x -10.9x
ASTC Unlock Forecast - 30 Days FREE Trial $8M 28.9x 0.3x
AVTR Unlock Forecast - 30 Days FREE Trial $8395M 12.2x 1.3x
AXDX Unlock Forecast - 30 Days FREE Trial $0M -0.2x 0.0x
BIO Unlock Forecast - 30 Days FREE Trial $7734M 24.2x 1.1x
BIO-B Unlock Forecast - 30 Days FREE Trial $6816M 21.4x 1.0x
BNGO Unlock Forecast - 30 Days FREE Trial $16M 0.0x 0.3x
BRKR Unlock Forecast - 30 Days FREE Trial $6145M 28.3x 3.2x
CTKB Unlock Forecast - 30 Days FREE Trial $503M 82.0x 1.3x
EYPT Unlock Forecast - 30 Days FREE Trial $920M -4.4x 3.7x
HBIO Unlock Forecast - 30 Days FREE Trial $21M -8.3x 1.4x
ILMN Unlock Forecast - 30 Days FREE Trial $15029M 12.0x 6.7x
LAB Unlock Forecast - 30 Days FREE Trial $492M -2.4x 1.2x
LCTC Unlock Forecast - 30 Days FREE Trial $9M x 1.5x
MTD Unlock Forecast - 30 Days FREE Trial $24913M 31.5x -136.9x
NAUT Unlock Forecast - 30 Days FREE Trial $91M -3.8x 0.5x
OMIC Unlock Forecast - 30 Days FREE Trial $50M -1.7x 0.4x
PACB Unlock Forecast - 30 Days FREE Trial $351M -1.5x 5.7x
PRPO Unlock Forecast - 30 Days FREE Trial $22M -1.2x 0.6x
QTRX Unlock Forecast - 30 Days FREE Trial $209M -11.1x 0.7x
RPID Unlock Forecast - 30 Days FREE Trial $134M -0.9x 2.5x
RVTY Unlock Forecast - 30 Days FREE Trial $9852M 34.5x 1.3x
SEER Unlock Forecast - 30 Days FREE Trial $129M -2.0x 0.4x
TXG Unlock Forecast - 30 Days FREE Trial $1571M -8.6x 2.0x
WAT Unlock Forecast - 30 Days FREE Trial $17631M 26.7x 8.2x

Frequently Asked Questions - 10x Genomics, Inc. Stock Forecast

How accurate are 10x Genomics, Inc. stock predictions?

Our AI model demonstrates 63% historical accuracy for TXG predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

What factors influence 10x Genomics, Inc. stock price forecasts?

Our analysis considers 10x Genomics, Inc.'s financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is 10x Genomics, Inc. a good investment in 2025?

Based on our AI analysis, 10x Genomics, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are 10x Genomics, Inc. forecasts updated?

10x Genomics, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced 10x Genomics, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for 10x Genomics, Inc. stock.

My Portfolio

Investment Dashboard

Loading your portfolio...